{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:56:55Z","timestamp":1792673815134,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Oncolytics"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.omto.2022.10.006","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T12:51:41Z","timestamp":1666270301000},"page":"182-194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Cross-study safety analysis of risk factors in CAR T\u00a0cell clinical trials: An FDA database pilot project"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1865-6169","authenticated-orcid":false,"given":"Matthew","family":"Foster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonatan","family":"Negash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Eberhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson W.","family":"Bryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3237-1960","authenticated-orcid":false,"given":"Bindu","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omto.2022.10.006_bib1","series-title":"FDA Approves Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma","year":"2022"},{"key":"10.1016\/j.omto.2022.10.006_bib2","series-title":"FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma","year":"2020"},{"key":"10.1016\/j.omto.2022.10.006_bib3","series-title":"FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Large B-Cell Lymphoma","year":"2021"},{"key":"10.1016\/j.omto.2022.10.006_bib4","series-title":"FDA Approves Idecabtagene Vicleucel for Multiple Myeloma","year":"2021"},{"key":"10.1016\/j.omto.2022.10.006_bib5","series-title":"FDA Approval Brings First Gene Therapy to the United States","year":"2017"},{"key":"10.1016\/j.omto.2022.10.006_bib6","series-title":"FDA Approves Axicabtagene Ciloleucel for Large B-Cell Lymphoma","year":"2017"},{"key":"10.1016\/j.omto.2022.10.006_bib7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/ITT.S202015","article-title":"Cytokine release syndrome: current perspectives","volume":"8","author":"Murthy","year":"2019","journal-title":"Immunotargets Ther."},{"key":"10.1016\/j.omto.2022.10.006_bib8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.omto.2022.10.006_bib9","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omto.2022.10.006_bib10","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.omto.2022.10.006_bib11","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1080\/14712598.2020.1729735","article-title":"Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy","volume":"20","author":"Chou","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.omto.2022.10.006_bib12","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omto.2022.10.006_bib13","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omto.2022.10.006_bib14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev."},{"key":"10.1016\/j.omto.2022.10.006_bib15","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.4049\/jimmunol.2001249","article-title":"Biomarkers for predicting cytokine release syndrome following CD19-targeted CAR T\u00a0cell therapy","volume":"206","author":"Tedesco","year":"2021","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omto.2022.10.006_bib16","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","article-title":"CRP and ferritin in addition to the EASIX score predict CAR-T\u2013related toxicity","volume":"5","author":"Greenbaum","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.omto.2022.10.006_bib17","unstructured":"Thompson Reuters. FDA Proposes New Databases to Monitor CAR T-Cell Safety across INDs (US). Practical Law Life Sciences W-001-6501. https:\/\/uk.practicallaw.thomsonreuters.com\/w-001-6501."},{"key":"10.1016\/j.omto.2022.10.006_bib18","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41392-020-00256-x","article-title":"The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma","volume":"5","author":"Wei","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omto.2022.10.006_bib19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40364-018-0116-0","article-title":"Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy","volume":"6","author":"Wang","year":"2018","journal-title":"Biomark. Res."},{"key":"10.1016\/j.omto.2022.10.006_bib20","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/bcp.12150","article-title":"Overview of methods for comparing the efficacies of drugs in the absence of head-to-head clinical trial data","volume":"77","author":"Kim","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.omto.2022.10.006_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/oxfordjournals.epirev.a036298","article-title":"Quantitative methods in the review of epidemiologic literature","volume":"9","author":"Greenland","year":"1987","journal-title":"Epidemiol. Rev."},{"issue":"Suppl 1","key":"10.1016\/j.omto.2022.10.006_bib22","first-page":"29","article-title":"Meta-analysis in medical research","volume":"14","author":"Haidich","year":"2010","journal-title":"Hippokratia"},{"key":"10.1016\/j.omto.2022.10.006_bib23","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/9781119536604.ch26","article-title":"Individual participant data","author":"Tierney","year":"2019","journal-title":"Cochrane Handbook Syst. Rev. Interventions"},{"key":"10.1016\/j.omto.2022.10.006_bib24","first-page":"604","article-title":"Why, when and how to adjust your P values?","volume":"20","author":"Jafari","year":"2019","journal-title":"Cell J."},{"key":"10.1016\/j.omto.2022.10.006_bib25","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719841581","article-title":"CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products","volume":"10","author":"Chavez","year":"2019","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.omto.2022.10.006_bib26","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/nrclinonc.2018.19","article-title":"Toxicity management after chimeric antigen receptor T\u00a0cell therapy: one size does not fit 'ALL","volume":"15","author":"Teachey","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omto.2022.10.006_bib27","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2022.10.006_bib28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2022.10.006_bib29","doi-asserted-by":"crossref","first-page":"S169","DOI":"10.1016\/j.bbmt.2018.12.308","article-title":"CD19 directed chimeric antigen receptor T\u00a0cell therapy in acute lymphoblastic leukemia: a systematic review and meta-analysis","volume":"25","author":"Anagnostou","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omto.2022.10.006_bib30","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/PPO.0000000000000508","article-title":"Chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia: current landscape in 2021","volume":"27","author":"Gauthier","year":"2021","journal-title":"Cancer J."},{"key":"10.1016\/j.omto.2022.10.006_bib31","first-page":"294","article-title":"Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T\u00a0cell therapy: a systematic review","volume":"28","author":"Grant","year":"2022","journal-title":"Transpl. Cell. Ther."},{"key":"10.1016\/j.omto.2022.10.006_bib32","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omto.2022.10.006_bib33","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/jamaneurol.2020.2703","article-title":"Clinical predictors of neurotoxicity after chimeric antigen receptor T-cell therapy","volume":"77","author":"Rubin","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.omto.2022.10.006_bib34","doi-asserted-by":"crossref","first-page":"7532","DOI":"10.1200\/JCO.2021.39.15_suppl.7532","article-title":"CD19 CAR T-cell product type independently impacts CRS and ICANS severity in patients with aggressive NHL","volume":"39","author":"Gauthier","year":"2021","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2022.10.006_bib35","doi-asserted-by":"crossref","first-page":"745320","DOI":"10.3389\/fimmu.2021.745320","article-title":"Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-hodgkin lymphoma","volume":"12","author":"Caimi","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omto.2022.10.006_bib36","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omto.2022.10.006_bib37","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1182\/blood.V128.22.586.586","article-title":"Decreased rates of severe CRS seen with early intervention strategies for CD19 CAR-T cell toxicity management","volume":"128","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.omto.2022.10.006_bib38","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.2019001463","article-title":"Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy","volume":"134","author":"Gardner","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.omto.2022.10.006_bib39","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.jcyt.2019.04.009","article-title":"Early administration of tocilizumab (Toci) for the prevention of grade 4 cytokine release syndrome (CRS) after CD19-directed CAR T-cell therapy (CTL019)","volume":"21","author":"Kadauke","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.omto.2022.10.006_bib40","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omto.2022.10.006_bib41","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T\u00a0cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in\u00a0vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.omto.2022.10.006_bib42","doi-asserted-by":"crossref","first-page":"320ra3","DOI":"10.1126\/scitranslmed.aad5222","article-title":"Early memory phenotypes drive T\u00a0cell proliferation in patients with pediatric malignancies","volume":"8","author":"Singh","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omto.2022.10.006_bib43","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T\u00a0cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omto.2022.10.006_bib44","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-Cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2022.10.006_bib45","doi-asserted-by":"crossref","first-page":"e150807","DOI":"10.1172\/JCI150807","article-title":"CAR T-cell manufacturing from naive\/stem memory T-lymphocytes enhances antitumor responses while curtailing cytokine release syndrome","volume":"132","author":"Arcangeli","year":"2022","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omto.2022.10.006_bib46","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.omto.2022.10.006_bib47","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","article-title":"Grading of cytokine release syndrome associated with the CAR T\u00a0cell therapy tisagenlecleucel","volume":"11","author":"Porter","year":"2018","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.omto.2022.10.006_bib48","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omto.2022.10.006_bib49","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1182\/bloodadvances.2019001304","article-title":"Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial","volume":"4","author":"Schuster","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.omto.2022.10.006_bib50","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2022.10.006_bib53","author":"Corporation"},{"key":"10.1016\/j.omto.2022.10.006_bib56","doi-asserted-by":"crossref","first-page":"e05209","DOI":"10.1002\/ccr3.5209","article-title":"Hemophagocytic lymphohistiocytosis\/macrophage activation syndrome (HLH\/MAS) following treatment with tisagenlecleucel","volume":"10","author":"Mart\u00edn-Rojas","year":"2022","journal-title":"Clin. Case Rep."},{"key":"10.1016\/j.omto.2022.10.006_bib57","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3389\/fimmu.2020.00524","volume":"11","author":"Sandler","year":"2020","journal-title":"Front. Immunol."}],"container-title":["Molecular Therapy - Oncolytics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770522001280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770522001280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:24:13Z","timestamp":1762496653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2372770522001280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":53,"alternative-id":["S2372770522001280"],"URL":"https:\/\/doi.org\/10.1016\/j.omto.2022.10.006","relation":{},"ISSN":["2372-7705"],"issn-type":[{"value":"2372-7705","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cross-study safety analysis of risk factors in CAR T\u00a0cell clinical trials: An FDA database pilot project","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Oncolytics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omto.2022.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}